TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28595339
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT-D)
Study: 18466078
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of hypothyroidism
Study: 16549905
Drug: AST-120 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST-120 (3 g t.i.d.)
Study: 27754709
Drug: Enzyme-Modified Ginseng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme-Modified Ginseng Extract (EMGE) 2,000 mg/day for 4 weeks
Study: 23363720
Drug: Intensive intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive intervention (4 CAD lectures, CAD outpatient visit twice a month, monthly telephone instructions)
Study: 18264012
Drug: Subcutaneous histamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous histamine (1‐10 ng twice a week)
Study: 18264012
Drug: Oral topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral topiramate (100 mg daily)
Study: 19841763
Drug: High frequency
Normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL SOLUTION [enMotion Foam High Frequency Use]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High frequency ultrasonic agitation applied with a 1 MHz therapeutic ultrasonic device on the dentin surfaces using G-Bond adhesive.
Study: 19841763
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group using bonding procedures according to manufacturers' instructions for G-Bond adhesive.
Study: 15206986
Drug: Solifenacin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin (10 mg) administered in fasting state
Study: 15206986
Drug: Solifenacin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin (10 mg) administered in fed state
Study: 9134633
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation (INR 2.5-4.0)
Study: 9134633
Drug: Heparin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin administration (APTT 1.5-2.5 x control)
Study: 9134633
Drug: Women using
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women using oral contraceptives
Study: 7898965
Drug: Surfactant therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant therapy (two doses of Exosurf rescue surfactant)
Study: 7898965
Drug: Air placebo
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air placebo (two doses of air)
Study: 3112934
Drug: Ordinary sugar
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary sugar coated penicillin tablets
Study: 30666859
Drug: Bioptron light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioptron light treatment in addition to full mouth scaling and root planing (FMSRP)
Study: 16505499
Drug: 500 or
Normalized name: C-500 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 or 1,000 mcg chromium daily (chromium picolinate)
Study: 11757828
Drug: 1.5 L
Normalized name: NUTREN 1.5 LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 L fill volume
Study: 11757828
Drug: 2.0 L
Normalized name: NUTREN 2.0 LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 L fill volume
Study: 7957545
Drug: Amiloride 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride 15 mg daily
Study: 22388343
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (0.8 mg)
Study: 8493625
Drug: Oral salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral salbutamol (8 mg)
Study: 20029224
Drug: Metformin continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin continued throughout pregnancy
Study: 20029224
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Metformin stopped in first trimester or conceived spontaneously without Metformin)
Study: 20029224
Drug: Metformin continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin continued in women with prior history of miscarriage
Study: 788732
Drug: Pralidoxime mesylate
Normalized name: pralidoxime mesylate
DrugBank: Pralidoxime (DB00733)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pralidoxime mesylate (P2S) 750 mg and atropine sulphate 2.0 mg
Study: 25213055
Drug: Dapsone 100
Normalized name: dapsone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone 100 mg daily for 6 weeks
Study: 22907440
Drug: Prokinetic with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prokinetic with split-dose PEG (100 mg itopride administered twice with each split-dose of PEG)
Study: 22907440
Drug: Split-dose PEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose PEG alone
Study: 12921618
Drug: Modified anti-shock
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified anti-shock programme (urine output maintained at 100 ml/h)
Study: 12921618
Drug: Traditional resuscitation
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional resuscitation formula (urine output maintained at 40 ml/h)
Study: 12575374
Drug: New Zhengtian
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Zhengtian Pill (NZTP)
Study: 12575374
Drug: Fuguiqin Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuguiqin Capsule (Control)
Study: 9364538
Drug: Docetaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (100 mg/m2 for 1 hour every 3 weeks)
Study: 9364538
Drug: Mitomycin (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin (12 mg/m2 every 6 weeks) plus Vinblastine (6 mg/m2 every 3 weeks)
Study: 3753801
Drug: Ivermectin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (200 micrograms per kilogram of body weight, single oral dose)
Study: 3892293
Drug: Diethylcarbamazine (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylcarbamazine (daily for eight days)
Study: 31638970
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment and radiation for Oral Cancer
Study: 31638970
Drug: Self-treatment prior
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-treatment prior to specialist consultation
Study: 31638970
Drug: Treatment initiation
Normalized name: Otezla 10mg-20mg 28-Day Treatment Initiation Pack Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment initiation after confirmed diagnosis
Study: 31638970
Drug: Financial expenditure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Financial expenditure on treatment
Study: 22453581
Drug: clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clindamycin phosphate 1.2%/BPO 2.5% gel
Study: 20214078
Drug: Needle retention
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle retention time in acupuncture treatment
Study: 16249145
Drug: Topical caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical caffeine 10%
Study: 2852389
Drug: Inhaled budesonide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide, 800 micrograms twice daily
Study: 2024740
Drug: Epidural diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural diamorphine 3 mg
Study: 19346952
Drug: Miglustat (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglustat (200 mg TID)
Study: 15338068
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg cimetidine i.v. + 0.1 mg/kg dimetindene i.v. 20 min before induction of anaesthesia (Group 1)
Study: 15338068
Drug: 1.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg/kg ranitidine i.v. + 0.1 mg/kg dimetindene i.v. 20 min before induction of anaesthesia (Group 2)
Study: 15338068
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ranitidine p.o. + 0.1 mg/kg dimetindene i.v. 1 to 2 h before induction of anaesthesia (Group 3)
Study: 15338068
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml saline solution i.v. 20 min before induction of anaesthesia (Control Group 4)
Study: 9039510
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) + Oxandrolone (Ox) 0.0625 mg/kg/day po
Study: 9039510
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) + Testosterone (T) 5 mg i.m. every 14 days
Study: 3066966
Drug: isoptin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: isoptin (10 mg)
Study: 3066966
Drug: obsidan (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: obsidan (5 mg)
Study: 25790670
Drug: Xinfeng Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinfeng Capsule (XFC) - 3 pills each time, 3 times a day for 3 months
Study: 25790670
Drug: SASP (sulfasalazine)
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SASP (sulfasalazine) - 4 tablets each time, twice a day for 3 months
Study: 21612139
Drug: 10 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL/kg of Ringer's lactate (RL)
Study: 21612139
Drug: 15 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL/kg of Ringer's lactate (RL)
Study: 21612139
Drug: 20 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL/kg of Ringer's lactate (RL)
Study: 19422345
Drug: Oral valganciclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valganciclovir (for 21 days) followed by once daily valganciclovir until day 49
Study: 19422345
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir (twice daily for 21 days)
Study: 19422345
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (valganciclovir and ganciclovir)
Study: 16949694
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of dose to the penile bulb and crura
Study: 15719855
Drug: Intra-articular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular morphine (10 mg)
Study: 11564483
Drug: levodopa 100
Normalized name: levodopa 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: levodopa 100 mg
Study: 9643623
Drug: Verapamil SR
Normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil SR 180 mg and trandolapril 0.5 mg
Study: 9643623
Drug: Verapamil SR
Normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil SR 180 mg and trandolapril 1.0 mg
Study: 9643623
Drug: Verapamil SR
Normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil SR (120, 180 mg) and trandolapril (0.5, 1.0, 2.0 mg)
Study: 3062528
Drug: Topical 0.5%
Normalized name: phenol topical 0.5% topical spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.5% levobunolol before unilateral Nd:YAG laser posterior capsulotomy
Study: 3062528
Drug: Topical 0.5%
Normalized name: phenol topical 0.5% topical spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.5% levobunolol after unilateral ECCE
Study: 21577010
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg opipramol
Study: 11273498
Drug: Interferon-alpha (IFN)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFN) therapy, 5 million units (MU) subcutaneously thrice a week for 12 weeks
Study: 11273498
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy (Control)
Study: 9109139
Drug: Amoxicillin once
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin once daily (qd)
Study: 9109139
Drug: Amoxicillin twice
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin twice daily (bid)
Study: 9109139
Drug: Amoxicillin (qd
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (qd or bid)
Study: 9109139
Drug: Amoxicillin (qd)
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin (qd) vs. Amoxicillin (bid)
Study: 9109139
Drug: Amoxicillin (qd
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (qd or bid) vs. Placebo
Study: 1394811
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Adriamycin (ADM) + 200 mg cytosine arabinoside (CA) in 30 ml physiological saline (group A)
Study: 1394811
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg peplomycin (PEP) + 200 mg CA in 30 ml physiological saline (group B)
Study: 1394811
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg neocarzinostatin (NCS) + 200 mg CA in 30 ml physiological saline (group C)
Study: 1394811
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ADM + 200 mg CA in 30 ml physiological saline + 300 mg/day UFT (group E)
Study: 1394811
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ADM + 200 mg CA in 30 ml physiological saline + 200 mg 5‐fluorouracil (5‐FU)/day (group F)
Study: 1394811
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ADM + 200 mg CA in 30 ml physiological saline + 30 mg ubenimex/day (group G)
Study: 1394811
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral drug (group H)
Study: 3840612
Drug: Bromopride (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromopride (20 mg) administered via i.v. injection half an hour before chemotherapy and at 3 1/2 and 7 1/2 hours following chemotherapy.
Study: 3840612
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered via i.v. injection half an hour before chemotherapy and at 3 1/2 and 7 1/2 hours following chemotherapy.
Study: 3840612
Drug: Bromopride (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromopride (20 mg)
Study: 22368996
Drug: Kinesiology treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesiology treatment for a period of 6 months
Study: 19373423
Drug: Control (placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo, H2 receptor antagonist, or somatostatin)
Study: 17499091
Drug: One-step self-etching
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-step self-etching adhesives (G-Bond, iBond, Clearfil S(3))
Study: 11590678
Drug: Beta-radiation therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-radiation therapy ((188)Re-MAG(3))
Study: 9833601
Drug: Acipimox (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (500 or 750 mg daily for 12 weeks)
Study: 9695160
Drug: Low-dose recombinant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose recombinant human growth hormone over eight weeks
Study: 1677821
Drug: Pancuronium (0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium (0.10 mg/kg)
Study: 1677821
Drug: Vecuronium (0.09
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.09 mg/kg)
Study: 6307135
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g twice daily
Study: 6307135
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 g once daily
Study: 6307135
Drug: Ceftriaxone therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone therapy continued after discharge
Study: 6307135
Drug: Ceftriaxone therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone therapy
Study: 30128705
Drug: Talcom 75
Normalized name: Talco
DrugBank: Talc (DB09511)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Talcom 75 mg od + aspirin 100 mg od
Study: 30128705
Drug: Plavix 75
Normalized name: Plavix 75mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plavix 75 mg od + aspirin 100 mg od
Study: 21108204
Drug: Propofol (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (bolus 1 mg/kg, followed by increments containing 20% of the initial dose)
Study: 21108204
Drug: Etomidate (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (bolus 0.15 mg/kg, followed by increments containing 20% of the initial dose) and 1 mg/kg of fentanyl i.v. (single dose)
Study: 18751504
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of terbinafine (250 mg)
Study: 18751504
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of terbinafine (250 mg)
Study: 15998354
Drug: ACTH(1-24) 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTH(1-24) 1.0 mg intramuscularly daily for four days
Study: 15998354
Drug: ACTH(1-24) 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTH(1-24) 0.5 mg intramuscularly daily for four days
Study: 15998354
Drug: ACTH(1-24) 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTH(1-24) 0.1 mg intramuscularly daily for four days
Study: 15998354
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9% 1 ml intramuscularly daily for four days (Control)
Study: 15998354
Drug: ACTH(1-24) 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTH(1-24) 1.0 mg intramuscularly five times at an interval of four days
Study: 8043704
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate treatment for 4 weeks
Study: 3414571
Drug: Diet‐plus‐behavior (DB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet‐plus‐behavior (DB) therapy
Study: 3414571
Drug: Exercise‐plus‐diet‐plus‐behavior (EDB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise‐plus‐diet‐plus‐behavior (EDB) therapy
Study: 4877600
Drug: I.C.I. 50172
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.C.I. 50172 (20 mg)
Study: 4877600
Drug: I.C.I. 50172
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.C.I. 50172 (4 mg)
Study: 29119418
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) at doses of 3, 6, and 9 J/diode (135, 270, and 405 J/thigh) applied bilaterally to the quadriceps muscle before time-to-exhaustion tests.
Study: 29119418
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment applied bilaterally to the quadriceps muscle before time-to-exhaustion tests.
Study: 28237959
Drug: Benidipine 4-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benidipine 4-8 mg/day and fosinopril 20 mg/day
Study: 28237959
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 12.5-25 mg/day and fosinopril 20 mg/day
Study: 25337748
Drug: 4-month gatifloxacin-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-month gatifloxacin-containing regimen (400 mg per day)
Study: 12543744
Drug: 5% povidone-iodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% povidone-iodine (PI) solution
Study: 12543744
Drug: 1% povidone-iodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% povidone-iodine (PI) solution
Study: 1448587
Drug: Nebuhaler treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebuhaler treatment (1 mg of terbutaline and 80 micrograms of ipratropium bromide four times daily)
Study: 1448587
Drug: Salbutamol nebulizer
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol nebulizer solution (5 mg)
Study: 1448587
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide nebulizer (0.5 mg)
Study: 1448587
Drug: Mixed nebulizer
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed nebulizer treatment (salbutamol and ipratropium bromide)
Study: 1448587
Drug: Home nebulizer
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home nebulizer treatment (chosen by patients)
Study: 1448587
Drug: Usual inhaled
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual inhaled treatment (2 weeks prior to intervention)
Study: 30074540
Drug: RV5 vaccine
Normalized name: human-bovine reassortant rotavirus strain G1 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV5 vaccine first dose at <6 weeks
Study: 30074540
Drug: RV1 vaccine
Normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV1 vaccine with a 4-week interval between doses
Study: 30074540
Drug: RV5 vaccine
Normalized name: human-bovine reassortant rotavirus strain G1 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV5 vaccine first dose at 3-4 weeks
Study: 30074540
Drug: RV5 vaccine
Normalized name: human-bovine reassortant rotavirus strain G1 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV5 vaccine first dose at 5-7 weeks
Study: 30074540
Drug: RV5 vaccine
Normalized name: human-bovine reassortant rotavirus strain G1 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV5 vaccine first dose at 8 weeks
Study: 24669015
Drug: TR-FEC (paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: TR-FEC (paclitaxel 80 mg/m(2) i.v. and everolimus 30 mg PO weekly for 12 weeks, followed by FEC)
Study: 24669015
Drug: T-FEC (paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-FEC (paclitaxel 80 mg/m(2) i.v. weekly for 12 weeks, followed by FEC)
Study: 18005366
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (1 L clear liquids)
Study: 18005366
Drug: Purgative group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purgative group (1 L PEG)
Study: 9930904
Drug: Atropine (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (2.0 mg intravenously)